{
    "Trade/Device Name(s)": [
        "ImmuLisa Enhanced B2GP1 IgA Antibody ELISA",
        "ImmuLisa Enhanced B2GP1 IgG Antibody ELISA",
        "ImmuLisa Enhanced B2GP1 IgM Antibody ELISA",
        "ImmuLisa Enhanced B2GP1 IgA/IgG/IgM Antibody ELISA",
        "B2GP1 Antibody ELISA"
    ],
    "Submitter Information": "Immco Diagnostics, Inc.",
    "510(k) Number": "K162788",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MSV"
    ],
    "Summary Letter Date": "May 30, 2017",
    "Summary Letter Received Date": "May 31, 2017",
    "Submission Date": "June 14, 2017",
    "Regulation Number(s)": [
        "21 CFR 866.5660"
    ],
    "Regulation Name(s)": [
        "Multiple autoantibodies immunological test system"
    ],
    "Analyte Class(es)": [
        "autoimmune",
        "immunology"
    ],
    "Analyte(s)": [
        "\u03b22-GPI IgA antibodies",
        "\u03b22-GPI IgG antibodies",
        "\u03b22-GPI IgM antibodies",
        "\u03b22-GPI IgA/IgG/IgM antibodies"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked immunosorbent assay (ELISA)",
        "Solid phase immunoassay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Immco ImmuLisa Enhanced B2GP1 IgA/IgG/IgM Antibody ELISA assays for detection of \u03b22-GPI autoantibodies in human serum",
    "Indications for Use Summary": "Aids in the diagnosis of autoimmune thrombotic disorders associated with antiphospholipid syndrome (APS) and APS with systemic lupus erythematosus (SLE) by detecting \u03b22-GPI IgA, IgG, and/or IgM antibodies in human serum, to be used in conjunction with other laboratory tests and clinical findings.",
    "fda_folder": "Immunology"
}